(DOCS) Doximity - NYSE
Sector: Healthcare | Industry: Health Information Services | Exchange: NYSE (USA) | Market Cap: 3.745m USD | Total Return: -64.5% in 12m
Avg Turnover: 66.9M
EPS Trend: 97.4%
Qual. Beats: 0
Rev. Trend: 99.5%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Doximity, Inc. operates a digital platform for U.S. medical professionals, offering a personalized newsfeed with clinical content, peer updates, and sponsored material from pharmaceutical manufacturers and health systems. The company provides workflow tools such as Ask (a HIPAA-compliant AI assistant), Scribe (AI-powered clinical documentation), Telehealth, and AMiON (on-call scheduling). Its customer base includes physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. Originally incorporated as 3MD Communications, Inc., the company rebranded to Doximity in June 2010 and is headquartered in San Francisco, California.
Within the Health Care Technology sub-industry, Doximity functions as a professional networking and SaaS-style platform, monetizing through subscriptions sold to healthcare systems and pharmaceutical marketing services. The company is listed on the NYSE under the ticker DOCS and went public in June 2021.
- AI Scribe and Ask tools drive average revenue per user higher
- Pharma manufacturer marketing budgets pressure subscription renewal growth
- Abridge and Suki competition intensifies in clinical AI documentation market
| Net Income: 196.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.28 > 0.02 and ΔFCF/TA 7.16 > 1.0 |
| NWC/Revenue: 122.4% < 20% (prev 163.5%; Δ -41.06% < -1%) |
| CFO/TA 0.29 > 3% & CFO 326.5m > Net Income 196.1m |
| Net Debt (-738.4m) to EBITDA (266.1m): -2.78 < 3 |
| Current Ratio: 6.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.0m) vs 12m ago -3.92% < -2% |
| Gross Margin: 89.09% > 18% (prev 90.20%; Δ -1.11% > 0.5%) |
| Asset Turnover: 54.01% > 50% (prev 45.12%; Δ 8.89% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.70 (Total Current Assets 944.3m - Total Current Liabilities 155.0m) / Total Assets 1.12b |
| B: -0.05 (Retained Earnings -51.1m / Total Assets 1.12b) |
| C: 0.21 (EBIT TTM 250.0m / Avg Total Assets 1.19b) |
| D: 5.50 (Book Value of Equity 950.8m / Total Liabilities 172.8m) |
| Altman-Z'' = 11.64 = AAA |
| DSRI: 1.00 (Receivables 144.8m/128.4m, Revenue 644.9m/570.4m) |
| GMI: 1.01 (GM 90.20% / 89.09%) |
| AQI: 1.13 (AQ_t 0.14 / AQ_t-1 0.12) |
| SGI: 1.13 (Revenue 644.9m / 570.4m) |
| TATA: -0.12 (NI 196.1m - CFO 326.5m) / TA 1.12b) |
| Beneish M = -2.86 (Cap -4..+1) = A |
As of June 25, 2026, the stock is trading at USD 20.83 with a total of 2,070,419 shares traded. Over the past week, the price has changed by -0.29%, over one month by +6.71%, over three months by -14.42% and over the past year by -64.48%.
Current recommended Stop Loss: 19.10 (which is 8.3% or 1.8 ATR below the current price).
Doximity has received a consensus analysts rating of 3.68. Therefore, it is recommended to hold DOCS.
- StrongBuy: 5
- Buy: 3
- Hold: 11
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 25.4 | 22% |
P/E Trailing = 20.898
P/E Forward = 14.3266
P/S = 5.8078
P/B = 3.9389
P/EG = 0.5895
Revenue TTM = 644.9m USD
EBIT TTM = 250.0m USD
EBITDA TTM = 266.1m USD
Long Term Debt = 8.07m USD (estimated: total debt 10.2m - short term 2.11m)
Short Term Debt = 2.11m USD (from shortTermDebt, last quarter)
Debt = 10.2m USD (from shortLongTermDebtTotal, last quarter) (leases 10.2m already included)
Net Debt = -738.4m USD (calculated: Debt 10.2m - CCE 748.6m)
Enterprise Value = 3.01b USD (3.75b + Debt 10.2m - CCE 748.6m)
Interest Coverage Ratio = unknown (Ebit TTM 250.0m / Interest Expense TTM 0.0)
EV/FCF = 9.47x (Enterprise Value 3.01b / FCF TTM 317.5m)
FCF Yield = 10.56% (FCF TTM 317.5m / Enterprise Value 3.01b)
FCF Margin = 49.23% (FCF TTM 317.5m / Revenue TTM 644.9m)
Net Margin = 30.40% (Net Income TTM 196.1m / Revenue TTM 644.9m)
Gross Margin = 89.09% ((Revenue TTM 644.9m - Cost of Revenue TTM 70.3m) / Revenue TTM)
Gross Margin QoQ = 86.65% (prev 89.89%)
Tobins Q-Ratio = 2.68 (Enterprise Value 3.01b / Total Assets 1.12b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 10.2m)
Taxrate = 21.58% (54.0m / 250.0m)
NOPAT = 196.1m (EBIT 250.0m * (1 - 21.58%))
Current Ratio = 6.09 (Total Current Assets 944.3m / Total Current Liabilities 155.0m)
Debt / Equity = 0.01 (Debt 10.2m / totalStockholderEquity, last quarter 950.8m)
Debt / EBITDA = -2.78 (Net Debt -738.4m / EBITDA 266.1m)
Debt / FCF = -2.33 (Net Debt -738.4m / FCF TTM 317.5m)
Total Stockholder Equity = 1.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.42% (Net Income 196.1m / Total Assets 1.12b)
RoE = 19.36% (Net Income TTM 196.1m / Total Stockholder Equity 1.01b)
RoCE = 24.49% (EBIT 250.0m / Capital Employed (Equity 1.01b + L.T.Debt 8.07m))
RoIC = 20.89% (NOPAT 196.1m / Invested Capital 938.6m)
WACC = 12.07% (E(3.75b)/V(3.76b) * Re(12.10%) + D(10.2m)/V(3.76b) * Rd(0.0%) * (1-Tc(0.22)))
Discount Rate = 12.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -17.98 | Cagr: -1.21%
[DCF] Terminal Value 66.92% ; FCFF base≈297.2m ; Y1≈340.7m ; Y5≈501.4m
[DCF] Fair Price = 40.00 (EV 4.54b - Net Debt -738.4m = Equity 5.28b / Shares 132.0m; r=12.07% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.44 | EPS CAGR: 29.05% | SUE: -0.52 | # QB: 0
Revenue Correlation: 99.50 | Revenue CAGR: 16.64% | SUE: 0.26 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.30 | Chg30d=-12.36% | Revisions=-76% | Analysts=18
EPS next Quarter (2026-09-30): EPS=0.37 | Chg30d=-12.45% | Revisions=-78% | Analysts=18
EPS current Year (2027-03-31): EPS=1.43 | Chg30d=-11.61% | Revisions=-75% | GrowthEPS=-5.8% | GrowthRev=+4.0%
EPS next Year (2028-03-31): EPS=1.60 | Chg30d=-10.71% | Revisions=-67% | GrowthEPS=+11.4% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: -78%